Evidence map›Paper›PMID 31747684›Full record

ArticleInvestigative ophthalmology & visual science2019

Role of Translational Attenuation in Inherited Retinal Degeneration.

Christopher R Starr, Cyril N A Nyankerh, Xiaoping Qi, Yang Hu, Oleg S Gorbatyuk, Nahum Sonenberg, Michael E Boulton, Marina S Gorbatyuk

Open access · goldAbstract read
In one paragraph

Article in Investigative ophthalmology & visual science, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. GADD34 Ablation Exacerbates Retinal Degeneration in P23H RHO Mice.International journal of molecular sciences · 2022
    Article
  4. Article
  5. Article
  6. Review
  7. Targeting Lipid Metabolism for the Treatment of Age-Related Macular Degeneration: Insights from Preclinical Mouse Models.Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Christopher R StarrDepartment of Optometry and Vision Science, School of Optometry, University of Alabama at Birmingham, Birmingham, Alabama, United States.
Cyril N A NyankerhDepartment of Optometry and Vision Science, School of Optometry, University of Alabama at Birmingham, Birmingham, Alabama, United States.
Xiaoping QiDepartment of Ophthalmology, and Vision Sciences, School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, United States.
Yang HuDepartment of Ophthalmology, School of Medicine, Stanford University, Stanford, California, United States.
Oleg S GorbatyukDepartment of Optometry and Vision Science, School of Optometry, University of Alabama at Birmingham, Birmingham, Alabama, United States.
Nahum SonenbergDepartment of Biochemistry, McGill University, Montreal, Quebec, Canada.
Michael E BoultonDepartment of Ophthalmology, and Vision Sciences, School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, United States.
Marina S GorbatyukDepartment of Optometry and Vision Science, School of Optometry, University of Alabama at Birmingham, Birmingham, Alabama, United States.
University of Alabama at Birmingham · USMcGill University · CAStanford University · US

Funding

Visual Phenotyping CoreP30EY003039 · NEI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Paul Douglas Gamlin · 1985 to 2026
$16.9M
Stanford Vision Research CoreP30EY026877 · NEI · STANFORD UNIVERSITY · PI Jeffrey L Goldberg · 2017 to 2026
$8.0M
Neuroprotection by Modulating ER Stress in GlaucomaR01EY023295 · NEI · TEMPLE UNIV OF THE COMMONWEALTH · PI HU, YANG · 2013 to 2022
$3.8M
Post-translational histone modification in ocular tissues of mice exposed to arsenicalsR01EY027763 · NEI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI GORBATYUK, MARINA · 2018 to 2022
$2.0M
NEI NIH HHS P30 EY003039NEI NIH HHS P30 EY026877NEI NIH HHS R01 EY023295NEI NIH HHS R01 EY027763
6 · The paper itself

Abstract

Purpose: We reported previously that retinas of mice with inherited retinal degeneration make less protein than retinas of normal mice. Despite recent studies suggesting that diminished protein synthesis rates may contribute to neurologic disorders, a direct link between protein synthesis rates and the progression of neurodegeneration has not been established. Moreover, it remains unclear whether reduced protein synthesis could be involved in retinal pathogenesis. Dysregulation of AKT/mTOR signaling has been reported in the retina during retinal degeneration, but to what extent this signaling contributes to translational attenuation in these mice remains uncertain. Methods: C57BL/6J and rd16 mice were subcutaneously injected with anisomycin to chronically inhibit protein synthesis rates. An AAV2 construct encoding constitutively active 4ebp1 was subretinally delivered in wildtype animals to lower protein synthesis rates. 4ebp1/2 were knocked out in rd16 mice. Results: Anisomycin treatment lowered retinal translation rates, accelerated retinal degeneration in rd16 mice, and initiated cell death in the retinas of C57BL/6J mice. AAV-mediated transfer of constitutively active 4ebp1-4A into the subretinal space of wildtype animals inhibited protein synthesis, and led to reduced electroretinography amplitudes and fewer ONL nuclei. Finally, we report that restoring protein synthesis rates by knocking out 4ebp1/2 was associated with an approximately 2-fold increase in rhodopsin levels and a delay in retinal degeneration in rd16 mice. Conclusions: Our study indicates that protein synthesis inhibition is likely not a cell defense mechanism in the retina by which deteriorating photoreceptors survive, but may be harmful to degenerating retinas, and that restoring protein synthesis may have therapeutic potential in delaying the progression of retinal degeneration.

Indexed as

Adaptor Proteins, Signal TransducingAnimalsAnisomycinCell Cycle ProteinsCell DeathDependovirusElectroretinographyEukaryotic Initiation FactorsGene Expression RegulationInjections, SubcutaneousIn Situ Nick-End LabelingMiceMice, Inbred C57BLMice, KnockoutParvovirinaeProtein BiosynthesisAdaptor Proteins, Signal TransducingAnisomycinCell Cycle ProteinsEif4ebp1 protein, mouseEif4ebp2 protein, mouseEukaryotic Initiation FactorsProtein Synthesis InhibitorsRhodopsin

Identifiers

PMID31747684
PMCPMC6871337
OpenAlexW2989960243

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.